Astellas Pharma: net income 2022

In fiscal year 2022, the net income of the Japanese pharmaceutical company Astellas Pharma Inc. amounted to more than 224.6 billion Japanese yen, the second highest amount of the past decade. Within the observed period, figures peaked in fiscal 2018 at close to 250 billion yen.
The main areas of the Japanese pharmaceutical company include urology, immunology, cardiology, and infectious diseases.

Net income of Astellas Pharma Inc. from fiscal year 2013 to 2022 (in billion Japanese yen)

Characteristic	Net income in billion Japanese yen
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-

Download

Source

Show detailed source information?

Already a member?

Source

Use Ask Statista Research Service

Release date

April 2023

More information

Region

Japan

Survey time period

fiscal year 2013 to 2022; the company's fiscal year starts on April 1 of the stated year and ends on March 31 of the following year

Special properties

consolidated data

Supplementary notes

Astellas Pharma Inc. has adopted International Financial Reporting Standards (IFRS) since the fiscal year ended March 31, 2014. Figures up to fiscal year ended March 31 2014, are based on Japanese generally accepted accounting principles (J-GAAP).
Figures prior to FY 2021 come from the previous reporting.

100 Japanese yen equal 0.72 U.S. dollars or 0.67 euros as of June 2023.

Citation formats